EGFR and non-small cell lung carcinoma: Thanks to the discoveries of oncogenic driver mutations, the treatment of NSCLC has been revolutionized by molecularly targeted therapies (2), of which tyrosine kinase inhibitor (TKI) targeting epidermal growth factor receptor (EGFR) has been widely prescribed for NSCLC patients (3), especially in Asian patients whose EGFR mutation prevalence reached 35%–50% (4).